Covidien unveils positive data for angioplasty device; inx Medical wins U.S. approval for hemorrhoids tech;

@FierceMedDev: Neovasc reports higher 1Q revenues, lower expenses and losses. Story | Follow @FierceMedDev

@VarunSaxena2: St. Jude Medical sticking with renal denervation, releases EnligHTN study data at EuroPCR2014. Release | Follow @VarunSaxena2

@MichaelGFierce: Smallest, fastest nanomotor moves drugs and releases them on demand. Story from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Wound-care outfit Healogics is up for grabs with $1B pricetag. Article | Follow @EmilyWFierce

> Covidien ($COV) has released from a two-year study showing that its Stellarex drug-coated angioplasty balloon continues to be shown as safe and effective for treatment of peripheral arterial disease. Release

> The FDA has approved inx Medical's Nexus Hemorrhoid Ligator with EasyFire technology for the treatment of internal hemorrhoids. Release

Biotech News

@FierceBiotech: Editors @JohnCFierce, @DamianFierce and @EricPFierce will chat w/ experts and break down #ASCO2014. More to follow. Sponsored by @Covance. | Follow @FierceBiotech

@JohnCFierce: The R&D rankings: Big biotech once again makes Big Pharma look small. Report | Follow @JohnCFierce

@DamianFierce: So, who's going to run $CELG when Bob Hugin hangs it up? More | Follow @DamianFierce

@EmilyMFierce: ICYMI, this week's edition of FierceBiotech Research features lots of ASM2014 news. Report | Follow @EmilyMFierce

> Isis surges on promising head-to-head thrombosis drug study. Story

> Sarepta bets on DMD drug approval with a $25M plant buy. Article

> Third Rock builds a new West Coast biotech with an eye on cancer drugs. Story

Pharma News

@FiercePharma: Top story in FiercePharmaMarketing Weds: Who gets the likes when it comes to job hunting? Think J&J, Novartis and Biogen Idec. Article | Follow @FiercePharma

@TracyStaton: Here's an idea for AZ's full-of-promises execs: Tie pay to opportunity cost. More | Follow @TracyStaton

@EricPFierce: German Merck invests €50M in biologics capacity at Italy plant. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: CIA abandons use of vaccine programs for spying. Story from FierceVaccines | Follow @CarlyHFierce

> Delaware counts the cost of a Pfizer takeover of AstraZeneca. Item

> India commits to doubling its regulatory force. Story

> Roche becomes latest target of China corruption crackdown. Article

Pharma Manufacturing News

> Global sweep nabs 237 counterfeiting suspects. News

> Moderna names big names to manufacturing advisory board. Item

> Logistics company RXTPL rails at FDA for identifying it in drug seizure report. Article

> Teva recalls drugs made by India's Emcure over lab testing issues. Story

> India to double its drug inspection staff. Report

Vaccines News

> Pandemic flu vaccine research poses risk of unintended release. Story

> Glaxo announces 5-year price freeze for post-GAVI countries. Article

> CIA abandons use of vaccine programs for spying. More

> Sanofi C. diff vaccine shows immune response in PhII trial. Report

> Kymab, Gates Foundation to team up for malaria, HIV antigen discovery. Item

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.